Subcutaneous · GLP-1 agonist / GIP antagonist

Maridebart cafraglutide / MariTide

27 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.

Trials

Ongoing

Recruiting

Completed

Sites

1,522

Countries

Endpoints

438

Composite endpoints

Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.

Where the program stands

Trials by phase

Phase 1

Phase 2

Phase 3

Trials by status

Not yet recruiting

Recruiting

Active, not recruiting

Completed

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK

133

Weight & body composition

Cardiometabolic biomarkers

Glycemic / diabetes

Cardiovascular outcomes

Patient-reported / QoL

Heart failure

Other clinical outcomes

MASH / liver

Renal / kidney

Other (unclassified)

Top 20 metrics across this asset's endpoints

AUC₀-∞Safety/PK

Treatment-emergent AEs (any)Safety/PK

CmaxSafety/PK

Immunogenicity (ADA)Safety/PK

Body weight, % changeWeight

Serious AEs (any)Safety/PK

Plasma concentration (steady state)Safety/PK

Systolic BP, changeBiomarker

HbA1c, changeGlycemic

Waist circumference, changeWeight

hs-CRP, changeBiomarker

Fasting glucose, changeGlycemic

Triglycerides, changeBiomarker

Expanded / custom MACE compositeCV

BMI, changeWeight

Total cholesterol, changeBiomarker

Non-HDL cholesterol, changeBiomarker

HDL-C, changeBiomarker

Diastolic BP, changeBiomarker

Body weight, absolute change (kg)Weight

Programs for this asset

Every trial for this molecule, with the same search, filters, and sort as the Trials tab.

⌘K

27 of 27

GLP-1 and incretin trials
	Asset / Population	Eligibility highlight						Evidence
MARITIME-CVEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity	Maridebart cafraglutide / MariTide Cardiovascular disease, Obesity / overweight	BMI ≥27	Ph 3	Recruiting	777	Jun 2028	-
MARITIME-HFMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity	Maridebart cafraglutide / MariTide Heart failure, Obesity / overweight	BMI ≥30	Ph 3	Recruiting	605	Jun 2028	-
MARITIME-1Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight	Maridebart cafraglutide / MariTide Obesity / overweight	BMI ≥30	Ph 3	Active, not recruiting	243	Jan 2027	-
MARITIME-2Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight	Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes	BMI ≥27	Ph 3	Active, not recruiting	187	Jan 2027	-
NCT06660173A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)	Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes	BMI 23-50	Ph 2	Active, not recruiting	96	Oct 2025	-
NCT05669599Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus	Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes	BMI ≥30	Ph 2	Completed	78	Oct 2024	1
MARITIME-OSA-1Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy	Maridebart cafraglutide / MariTide Obesity / overweight, Sleep apnea	BMI ≥27	Ph 3	Recruiting	56	Sep 2027	-
MARITIME-OSA-2Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy	Maridebart cafraglutide / MariTide Obesity / overweight, Sleep apnea	-	Ph 3	Recruiting	49	Sep 2027	-
NCT07575399Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)	Maridebart cafraglutide / MariTide Obesity / overweight	BMI ≥25	Ph 3	Recruiting	40	Jan 2028	-
MARITIME-3-JEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease	Maridebart cafraglutide / MariTide Obesity / overweight	BMI ≥35	Ph 3	Active, not recruiting	30	Apr 2027	-
NCT07441252A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight	Maridebart cafraglutide / MariTide MASH / NAFLD / liver fibrosis, Obesity / overweight	BMI 27-40	Ph 2	Recruiting	21	Sep 2027	-
NCT07428525A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function	Maridebart cafraglutide / MariTide Healthy volunteers, Hepatic impairment	BMI ≥22	Ph 1	Completed	5	Feb 2026	-
NCT07429045A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body	Maridebart cafraglutide / MariTide Healthy volunteers, Renal impairment	BMI ≥22	Ph 1	Completed	5	Nov 2025	-
NCT07226778Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 25-40	Ph 1	Active, not recruiting	4	May 2026	-
NCT07313761A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 25-40	Ph 1	Active, not recruiting	4	Jun 2026	-
NCT07717814A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 25-40	Ph 1	Completed	4	May 2025	-
NCT04478708Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 30-40	Ph 1	Completed	3	Nov 2022	1	results
NCT06976372A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity	Maridebart cafraglutide / MariTide Obesity / overweight	BMI ≥27	Ph 1	Completed	3	Dec 2024	-
NCT07523711Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 25-35	Ph 1	Recruiting	3	Oct 2026	-
NCT07229157Effect of Maridebart Cafraglutide on the Heart's Electrical Activity	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 25-35	Ph 1	Active, not recruiting	2	Aug 2026	-
NCT07160257A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus	Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes	BMI 25-45	Ph 1	Recruiting	1	Nov 2026	-
NCT06352892A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 24-40	Ph 1	Completed	1	Aug 2024	-
NCT07429032The Effect of AMG 133 on Gastric Emptying	Maridebart cafraglutide / MariTide Obesity / overweight	BMI 27-40	Ph 1	Completed	1	Nov 2025	-
NCT05056246Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants	Maridebart cafraglutide / MariTide Healthy volunteers	BMI 18-30	Ph 1	Completed	1	Apr 2022	-	results
NCT07310563A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity	Maridebart cafraglutide / MariTide Obesity / overweight	BMI ≥25	Ph 1	Completed	1	May 2025	-

Showing 1-25 of 27 trials